Clinical Intelligence.

Synchronized research and peer-reviewed trials for modern professionals.

Clinical Coverage

Search drug updates and clinical coverage.

6 loaded

FDA Approves Etripamil (Cardamyst) for PSVT: Rapid Conversion to Sinus Rhythm in Outpatient Settings

FDA approves etripamil (Cardamyst) nasal spray for rapid conversion of paroxysmal supraventricular tachycardia episodes.

6h ago|4 min read|Dr. Kavya Sharma

Neurology

FDA Review of Tolebrutinib: Nonrelapsing Secondary Progressive MS Treatment

Tolebrutinib reduces disability progression in nonrelapsing secondary progressive MS by 30% in phase 3 trial.

6h ago|4 min read|Dr. Aditi Kulkarni

Oncology

Pembrolizumab Plus mRNA-4157 Reduces Melanoma Recurrence: 49% Reduction in KEYNOTE-942 Trial

Pembrolizumab plus mRNA-4157 reduces melanoma recurrence by 49% in KEYNOTE-942 trial, showing promise for high-risk patients.

6h ago|4 min read|Dr. Rahul Verma

Infectious Disease

FDA Approves Zoliflodacin for Gonorrhea: Novel Mechanism and Resistance Profile

Zoliflodacin achieves 97.8% cure rate for gonorrhea, offering a novel mechanism against resistant strains. FDA approval details and clinical implications discussed.

6h ago|4 min read|Dr. Simran Kohli

Neurology

FDA Approves Efgartigimod Alfa for Myasthenia Gravis: Home Administration for Seronegative Patients

Efgartigimod alfa (Vyvgart) approved for seronegative generalized myasthenia gravis, enabling home administration and improving patient outcomes.

6h ago|4 min read|Dr. Vikram Patel

Ophthalmology

FDA Approves Yuvezzi: First Dual-Agent Eye Drop for Presbyopia Management

Yuvezzi approved for presbyopia: first dual-agent eye drop shows 20% improvement in near vision.

6h ago|4 min read|Dr. Ravi Krishnan